The Latest Breaking News from Novo Nordisk

SAP’s finance chief, Dominik Asam, hopes tariffs are a “wake-up call” that can kick-start Europe into building more tech giants.

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

The Trump administration says it will raise Medicare Advantage payments sharply, good news for Humana, UnitedHealth and other health insurers.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and forcing the ECB to consider rate cuts.

The market appears to be underestimating just how much these two companies can grow.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.